thought leadership
Cell and gene therapy in the Asia-Pacific region: learnings from local case studies
Sudha Sundaram, Vesshnu Sutharsan, and Ye Huang | 2/20/2024
In this second update in our series, we share two case studies that explore how local innovators in the cell and gene therapy (CGT) space in Asia-Pacific (APAC) are addressing some of the major challenges for access in the region: that of overcoming complex manufacturing and delivery and improving affordability.
Many local players are advancing technology and improving access for cell and gene therapies in the Asia-Pacific region
APAC markets were some of the first globally to embrace CGTs, with China approving the world’s first gene therapy way back in 2003. Today, markets in the APAC region have a relatively large pharmaceutical expenditure, with China and Japan ranking among the five largest global pharmaceutical markets.
The region’s large and aging populations are driving an increasing demand for innovative therapies, including CGTs; APAC is estimated to have a compound annual growth rate of 56% over a 5-year period until 2026 for chimeric antigen receptor T-cell therapy (CAR-T) alone (vs a global CAGR of 39%).
Given the commercial potential of CGTs as innovative, life-changing therapies for patients in the region and beyond, it is no surprise that many local players have become actively engaged in advancing CGT technology and improving CGT access in the APAC region.
Overcoming manufacturing, delivery, and affordability challenges for cell and gene therapies in the Asia-Pacific region
Here are two case studies that explain how local innovators are addressing the major access challenges of overcoming complex manufacturing and delivery and improving affordability for CGTs in APAC.
This biotech company in the Asia-Pacific region is leveraging regional and public-private partnerships to establish cost-effective and scalable localized manufacturing in the cell and gene therapy space.
Vesshnu Sutharsan
Consultant
Case study 1: A spotlight on India
This biopharmaceutical manufacturer is leveraging city-level voluntary commercial health insurance to accelerate the adoption of transformative cell and gene therapies among patients in the Asia-Pacific region.
Ye Huang
Senior Consultant
Case study 2: A spotlight on China
Connect with us and stay at the forefront of advancements in the cell and gene therapy space in the Asia–Pacific region
To learn more about the evolving competitive landscape of CGTs in APAC and gain insights into the CGT capabilities of local biotechs and where their products are today, watch our webinar, “Exploring new horizons: Cell and gene therapy access in the Asia-Pacific region”. Alternatively, please contact our policy, access, value, and evidence experts in Singapore.
